Indian govt halts production in 40 pharma companies
In a major crackdown in India, manufacturing has been halted in at least 40 pharmaceutical companies, followed by the suspension or cancellation of licenses for 66 other firms, following a risk-based assessment of 162 drug firms.
Indian Minister of Health Mansukh Mandaviya informed Parliament that a First Information Report (FIR) has also been filed in one of the cases. An FIR is prepared by the police when they receive information about the commission of a cognisable offence.
Following inspections by the Central Drug Standard Control Organization (CDSCO), 21 warning letters have also been issued.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze